|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huber PE, Jenne JW, Rastert R,
Simiantonakis I, Sinn HP, Strittmatter HJ, von Fournier D,
Wannenmacher MF and Debus J: A new noninvasive approach in breast
cancer therapy using magnetic resonance imaging-guided focused
ultrasound surgery. Cancer Res. 61:8441–8447. 2001.PubMed/NCBI
|
|
3
|
Margenthaler JA: Optimizing conservative
breast surgery. J Surg Oncol. 103:306–312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma A, Koldovsky U, Xu S, Mick R, Roses
R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, et
al: HER-2 pulsed dendritic cell vaccine can eliminate HER-2
expression and impact ductal carcinoma in situ. Cancer.
118:4354–4362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aggarwal SR: A survey of breakthrough
therapy designations. Nat Biotechnol. 32:323–330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim MM, Allen P, Gonzalez-Angulo AM,
Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM,
Litton JK, Hortobagyi GN, et al: Pathologic complete response to
neoadjuvant chemotherapy with trastuzumab predicts for improved
survival in women with HER2-overexpressing breast cancer. Ann
Oncol. 24:1999–2004. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moreno-Aspitia A: Neoadjuvant therapy in
early-stage breast cancer. Crit Rev Oncol Hematol. 82:187–199.
2012. View Article : Google Scholar
|
|
8
|
Krug D, Baumann R, Budach W, Dunst J,
Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML,
et al: Current controversies in radiotherapy for breast cancer.
Radiat Oncol. 12:252017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shah C, Tendulkar R, Smile T, Nanavati A,
Manyam B, Balagamwala E, Pham Y, Takiar R, Wobb J, Khan A, et al:
Adjuvant radiotherapy in early-stage breast cancer: Evidence-based
options. Ann Surg Oncol. 23:3880–3890. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sparano JA, Zhao F, Martino S, Ligibel JA,
Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC and Davidson
NE: Long-term follow-up of the E1199 phase III trial evaluating the
role of taxane and schedule in operable breast cancer. J Clin
Oncol. 33:2353–2360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gligorov J and Richard S: Breast cancer:
Weekly paclitaxel-still preferred first-line taxane for mBC. Nat
Rev Clin Oncol. 12:508–509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wahl AF, Donaldson KL, Fairchild C, Lee
FY, Foster SA, Demers GW and Galloway DA: Loss of normal p53
function confers sensitization to Taxol by increasing G2/M arrest
and apoptosis. Nat Med. 2:72–79. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shannon KB, Canman JC, Ben Moree C,
Tirnauer JS and Salmon ED: Taxol-stabilized microtubules can
position the cytokinetic furrow in mammalian cells. Mol Biol Cell.
16:4423–4436. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang YF, Li LL, Wu CW, Liu TY, Lui WY,
P’eng FK and Chi CW: Paclitaxel-induced apoptosis in human gastric
carcinoma cell lines. Cancer. 77:14–18. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De Laurentiis M, Cancello G, D’Agostino D,
Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V,
Esposito A, Silvestro L, et al: Taxane-based combinations as
adjuvant chemotherapy of early breast cancer: A meta-analysis of
randomized trials. J Clin Oncol. 26:44–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moreno-Aspitia A and Perez EA:
Anthracycline- and/or taxane-resistant breast cancer: Results of a
literature review to determine the clinical challenges and current
treatment trends. Clin Ther. 31:1619–1640. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
De Duve C: The lysosome. Sci Am.
208:64–72. 1963. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Levy JMM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizushima N, Yoshimori T and Ohsumi Y: The
role of Atg proteins in autophagosome formation. Annu Rev Cell Dev
Biol. 27:107–132. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang XH, Kleeman LK, Jiang HH, Gordon G,
Goldman JE, Berry G, Herman B and Levine B: Protection against
fatal Sindbis virus encephalitis by beclin, a novel
Bcl-2-interacting protein. J Virol. 72:8586–8596. 1998.PubMed/NCBI
|
|
21
|
Kang R, Zeh HJ, Lotze MT and Tang D: The
Beclin 1 network regulates autophagy and apoptosis. Cell Death
Differ. 18:571–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh
H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al:
Promotion of tumorigenesis by heterozygous disruption of the beclin
1 autophagy gene. J Clin Invest. 112:1809–1820. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yue Z, Jin S, Yang C, Levine AJ and Heintz
N: Beclin 1, an autophagy gene essential for early embryonic
development, is a haploinsufficient tumor suppressor. Proc Natl
Acad Sci USA. 100:15077–15082. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Y, Liu JH, Jin L, Lin SM, Yang Y, Sui
YX and Shi H: Over-expression of the Beclin1 gene upregulates
chemosensitivity to anti-cancer drugs by enhancing therapy-induced
apoptosis in cervix squamous carcinoma CaSki cells. Cancer Lett.
294:204–210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Lin S and Chang S: Effect of
beclin 1 expression on the biological behavior and chemotherapy
sensitivity of cervical cancer cells. Oncol Lett. 11:4089–4094.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y
and He Y: Suberoylanilide hydroxamic acid sensitizes neuroblastoma
to paclitaxel by inhibiting thioredoxin-related protein 14-mediated
autophagy. Cancer Sci. 108:1485–1492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang SF, Wang XY, Fu ZQ, Peng QH, Zhang
JY, Ye F, Fu YF, Zhou CY, Lu WG, Cheng XD and Xie X: TXNDC17
promotes paclitaxel resistance via inducing autophagy in ovarian
cancer. Autophagy. 11:225–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xi G, Hu X, Wu B, Jiang H, Young CY, Pang
Y and Yuan H: Autophagy inhibition promotes paclitaxel-induced
apoptosis in cancer cells. Cancer Lett. 307:141–148. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song Y, Li W, Peng X, Xie J, Li H and Tan
G: Inhibition of autophagy results in a reversal of taxol
resistance in nasopha-ryngeal carcinoma by enhancing taxol-induced
caspase-dependent apoptosis. Am J Transl Res. 9:1934–1942.
2017.
|
|
31
|
Liu S and Li X: Autophagy inhibition
enhances sensitivity of endometrial carcinoma cells to paclitaxel.
Int J Oncol. 46:2399–2408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu C, Jin B, Chen L, Zhuo D, Zhang Z, Gong
K and Mao Z: MiR-30d induces apoptosis and is regulated by the
Akt/FOXO pathway in renal cell carcinoma. Cell Signal.
25:1212–1221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
34
|
Zhong Y, Wang QJ, Li X, Yan Y, Backer JM,
Chait BT, Heintz N and Yue Z: Distinct regulation of autophagic
activity by Atg14L and Rubicon associated with Beclin
1-phosphatidylinositol-3-kinase complex. Nat Cell Biol. 11:468–476.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maycotte P, Gearheart CM, Barnard R, Aryal
S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC,
Gustafson DL and Thorbun A: STAT3-mediated autophagy dependence
identifies subtypes of breast cancer where autophagy inhibition can
be efficacious. Cancer Res. 74:2579–2590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
National Research Council: Guide for the
Care and Use of Laboratory Animals. 8th edition. National Academies
Press; Washington, DC: 2011
|
|
37
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar
|
|
38
|
Bauer JA, Chakravarthy AB, Rosenbluth JM,
Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC,
Mayer IA, Meszoely IM, et al: Identification of markers of taxane
sensitivity using proteomic and genomic analyses of breast tumors
from patients receiving neoadjuvant paclitaxel and radiation. Clin
Cancer Res. 16:681–690. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hatzis C, Pusztai L, Valero V, Booser DJ,
Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, et
al: A genomic predictor of response and survival following
taxane-anthracycline chemotherapy for invasive breast cancer. JAMA.
305:1873–1881. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sootichote R, Thuwajit P, Singsuksawat E,
Warnnissorn M, Yenchitsomanus PT, Ithimakin S, Chantharasamee J and
Thuwajit C: Compound A attenuates toll-like receptor 4-mediated
paclitaxel resistance in breast cancer and melanoma through
suppression of IL-8. BMC Cancer. 18:2312018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wen J, Yeo S, Wang C, Chen S, Sun S, Haas
MA, Tu W, Jin F and Guan JL: Autophagy inhibition re-sensitizes
pulse stimulation-selected paclitaxel-resistant triple negative
breast cancer cells to chemotherapy-induced apoptosis. Breast
Cancer Res Treat. 149:619–629. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang S, Huang X, Lee CK and Liu B:
Elevated expression of erbB3 confers paclitaxel resistance in
erbB2-overexpressing breast cancer cells via upregulation of
Survivin. Oncogene. 29:4225–4236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
McGrogan BT, Gilmartin B, Carney DN and
McCann A: Taxanes, microtubules and chemoresistant breast cancer.
Biochim Biophys Acta. 1785:96–132. 2008.
|
|
44
|
Blagosklonny MV, Giannakakou P, el-Deiry
WS, Kingston DG, Higgs PI, Neckers L and Fojo T: Raf-1/bcl-2
phosphorylation: A step from microtubule damage to cell death.
Cancer Res. 57:130–135. 1997.PubMed/NCBI
|
|
45
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ranganathan S, Benetatos CA, Colarusso PJ,
Dexter DW and Hudes GR: Altered beta-tubulin isotype expression in
paclitaxel-resistant human prostate carcinoma cells. Br J Cancer.
77:562–566. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Aita VM, Liang XH, Murty VV, Pincus DL, Yu
W, Cayanis E, Kalachikov S, Gilliam TC and Levine B: Cloning and
genomic organization of beclin 1, a candidate tumor suppressor gene
on chromosome 17q21. Genomics. 59:59–65. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rai G, Mishra S, Suman S and Shukla Y:
Resveratrol improves the anticancer effects of doxorubicin in vitro
and in vivo models: A mechanistic insight. Phytomedicine.
23:233–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang A and Li J: Crocetin shifts
autophagic cell survival to death of breast cancer cells in
chemotherapy. Tumour Biol. 39:10104283176945362017.PubMed/NCBI
|
|
50
|
Veldhoen RA, Banman SL, Hemmerling DR,
Odsen R, Simmen T, Simmonds AJ, Underhill DA and Goping IS: The
chemotherapeutic agent paclitaxel inhibits autophagy through two
distinct mechanisms that regulate apoptosis. Oncogene. 32:736–746.
2013. View Article : Google Scholar
|
|
51
|
Aoudjit F and Vuori K: Integrin signaling
inhibits paclitaxel-induced apoptosis in breast cancer cells.
Oncogene. 20:4995–5004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pan Z, Avila A and Gollahon L: Paclitaxel
induces apoptosis in breast cancer cells through different
calcium-regulating mechanisms depending on external calcium
conditions. Int J Mol Sci. 15:2672–2694. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Oberstein A, Jeffrey PD and Shi Y: Crystal
structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a
novel BH3-only protein. J Biol Chem. 282:13123–13132. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhao XG, Sun RJ, Yang XY, Liu DY, Lei DP,
Jin T and Pan XL: Chloroquine-enhanced efficacy of cisplatin in the
treatment of hypopharyngeal carcinoma in xenograft mice. PLoS One.
10:e01261472015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang J, Pan XL, Ding LJ, Liu DY, Da-Peng L
and Jin T: Aberrant expression of Beclin-1 and LC3 correlates with
poor prognosis of human hypopharyngeal squamous cell carcinoma.
PLoS One. 8:e690382013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Witherby S, Rizack T, Sakr BJ, Legare RD
and Sikov WM: Advances in medical management of early stage and
advanced breast cancer: 2015. Semin Radiat Oncol. 26:59–70. 2016.
View Article : Google Scholar
|
